Clinical Aspects and Case Management in a Patient with Long QT Syndrome, Probably Genetic

1. Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?. Heart Rhythm. 2017 Jan. 14(1):e41-e44. [Medline].10.1016/j.hrthm.2016.09.01227659101Search in Google Scholar

2. Heemskerk CPM, Pereboom M, van Stralen K, et al. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018 Feb. 74(2):183-91. [Medline].2916791810.1007/s00228-017-2381-529167918Search in Google Scholar

3. El-Sherif N, Turitto G, Boutjdir M. Congenital long QT syndrome and torsade de pointes. Ann Noninvasive Electrocardiol. 2017 Nov. 22(6):[Medline].10.1111/anec.12481693159028670758Search in Google Scholar

4. Wei H, Wu J, Liu Z. Studying KCNQ1 mutation and drug response in type 1 long QT syndrome using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Methods Mol Biol. 2018. 1684:7-28. [Medline].10.1007/978-1-4939-7362-0_229058180Search in Google Scholar

5. Duncan G, Firth K, George V, et al. Drug-mediated shortening of action potentials in LQTS2 human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells Dev. 2017 Dec 1. 26(23):1695-705. [Medline].10.1089/scd.2017.0172570662928992755Open DOISearch in Google Scholar

6. Gong Q, Zhou Z. Nonsense-mediated mRNA decay of hERG mutations in long QT syndrome. Methods Mol Biol. 2018. 1684:37-49. [Medline].2905818210.1007/978-1-4939-7362-0_429058182Search in Google Scholar

7. Fukumoto D, Ding WG, Wada Y, et al. Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome. J Cardiol. 2018 Apr. 71(4):401-8. [Medline].10.1016/j.jjcc.2017.10.00429146210Search in Google Scholar

8. Perez-Riera AR, Barbosa-Barros R, Daminello Raimundo R, da Costa de Rezende Barbosa MP, Esposito Sorpreso IC, de Abreu LC. The congenital long QT syndrome Type 3: An update. Indian Pacing Electrophysiol J. 2018 Jan - Feb. 18(1):25-35. [Medline]. [Full Text].10.1016/j.ipej.2017.10.011584085229101013Search in Google Scholar

9. Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006 Nov 14. 114(20):2104-12. [Medline].10.1161/CIRCULATIONAHA.106.63526817060380Search in Google Scholar

10. Napolitano C, Bloise R, Priori SG. Long QT syndrome and short QT syndrome: how to make correct diagnosis and what about eligibility for sports activity. J Cardiovasc Med (Hagerstown). 2006 Apr. 7(4):250-6. [Medline].10.2459/01.JCM.0000219317.12504.5f16645398Search in Google Scholar

11. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006 Jan. 259(1):59-69. [Medline].10.1111/j.1365-2796.2005.01589.x16336514Search in Google Scholar

12. Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med. 2006 Jan. 259(1):39-47. [Medline]10.1111/j.1365-2796.2005.01583.x16336512Search in Google Scholar

13. https://emedicine.medscape.com/article/157826-overview#a4Search in Google Scholar